Today’s post is about another example of how evolution can play jokes on us. It really is the case that a signaling pathway that controls hair growth is the same that determines the number and shape of dendritic spines in the brain.
This is good news not just for Homer Simpson but for people interesting in perking up behavior and cognitive function in autism.
The post also connects several subjects that we have previously encountered - dendritic spines which are abnormal in autism, Wnt signaling which is implicated in cancer (and autism), statins, Ivermectin, CAPE found in some propolis and verapamil. There is plenty of research to back all these connections, but strangely nobody seems to be applying them to develop any practical therapies.
I introduced dendritic spines in an earlier post. Each neuron in your brain has hundreds of protruding spines.
Dendritic Spines in Autism – Why, and potentially how, to modify them
In that post I reported that PAK1, the gene NrCAM and the protein MTOR were all implicated in the dysfunction in both shape and number of these spines.
It now seems that there may be one even more critical pathway involved – Wnt. There are links between Wnt and PAK1, that appeared in several earlier posts.
You may recall that dendritic spines are constantly changing shape. Their shape affects their function. In many disorders, both the number and shape of the spines is dysfunctional. It appears that the morphology (shape) can be modified, which implies you could affect behavior, memory, and cognitive function.
My follow up post of dendritic spines has yet to materialize, but here is a sneak preview, showing the progression of autism, schizophrenia and Alzheimer’s in terms of the number of dendritic spines.
Dendritic Spines and Wnt Signaling
Dendritic spines are constantly changing their shape and certain psychiatric disorders are characterized by different morphologies (shapes) of these spines. It is not just the number of spines, but their shape which affects cognitive function, memory and behavior.
The Wnt signaling pathway also lies behind hair growth.
What is more, we know that Wnt signaling is dysfunctional in autism and we even now which the genes are that likely trigger of this dysfunction.
Wnt dysfunction is also involved in many types of cancer and therefore has been subject of much research.
The surprise came when I read that attempts are underway to “tune” Wnt signaling to control hair growth. Why not autism?
This post is about tuning Wnt signaling to improve cognitive function and behavior. This appears just as plausible as controlling hair growth.
The Wnt Signaling Pathways
Here is the Wikipedia explanation.
Wnt signaling pathway
Wnt signaling was first identified for its role in carcinogenesis, but has since been recognized for its function in embryonic development. The embryonic processes it controls include body axis patterning, cell fate specification, cell proliferation, and cell migration. These processes are necessary for proper formation of important tissues including bone, heart, and muscle. Its role in embryonic development was discovered when genetic mutations in proteins in the Wnt pathway produced abnormal fruit fly embryos. Later research found that the genes responsible for these abnormalities also influenced breast cancer development in mice.
The clinical importance of this pathway has been demonstrated by mutations that lead to a variety of diseases, including breast and prostate cancer, glioblastoma, type II diabetes, and others.[3][4]
The Canonical Wnt pathway is dysfunctional in Autism
It is the canonical Wnt pathway that is dysfunction in autism and it is this same pathway plays a role in dendrite growth and suboptimal Wnt activity negatively affects the dendritic arbor.
A very thorough review of all the genetic evidence is provided in the following study:
Notably, the available genetic information indicates that not only canonical Wnt pathway activation, but also inhibition seems to increase autism risk. The canonical Wnt pathway plays a role in dendrite growth and suboptimal activity negatively affects the dendritic arbor. In principle, this provides a logical explanation as to why both hypo- and hyperactivity may generate a similar set of behavioral and cognitive symptoms.
The review highlights that, as we have seen before, some people with autism are hypo and some people are hyper; this means some people need Wnt signaling to be inhibited and other people need the opposite therapy. The author points out that you really need some test to check which way you need your Wnt “tuned”.
It sounds a bit like tuning the timing of the sparks inside your car engine, in the days before it was all electronic and self-tuning. In theory you needed to measure the timing of the sparks with a special strobe light; but if you knew what you were doing you could just use your ears. So in the same vein, you could make a small change to inhibit Wnt and see the result, if it made matters worse you just stop and go the other way. As you will see later in this post, some of us are already tuning Wnt without even realizing it.
It sounds a bit like tuning the timing of the sparks inside your car engine, in the days before it was all electronic and self-tuning. In theory you needed to measure the timing of the sparks with a special strobe light; but if you knew what you were doing you could just use your ears. So in the same vein, you could make a small change to inhibit Wnt and see the result, if it made matters worse you just stop and go the other way. As you will see later in this post, some of us are already tuning Wnt without even realizing it.
We have exactly the same issue with mGluR5, where you might need a positive/negative allosteric modulator to optimize brain performance. Different variants of “autism” would be located either left or right of “top dead center”.
In that post we learnt that at MIT they are suggesting that errors in synaptic protein synthesis are behind several types of autism and that these errors can be corrected using either positive or negative stimulators of the receptor mGluR5.
Ketamine, Memantine, D-Cycloserin, Magnesium, Fenobam and yet more as Glutamatergic Modulators in Autism (and Fragile X)
For a more detailed understanding of Wnt signaling, see the paper below:-
For Homer Simpson and others wanting more hair
Abnormal hair development and regeneration has been implicated in diseases of the skin (ie., hirsutism, alopecia, etc) or in open wounds when hair follicles are completely eliminated. To manage these clinical conditions, it is important to understand molecular pathways which regulate the number, size, growth and regeneration of hair follicles. Wnt signaling plays a fundamental role in this process. We need a deeper understanding so we can reliably adjust Wnt levels in existing follicles. This studies reviewed here have future translational value for skin regeneration following severe wound injuries or in the context of tissue engineering. Tuning the levels of Wnt ligands can directly modulate the number and growth of hairs. Using this new knowledge, we now know that Wnt activity can be modulated by adjusting the secretion of Wnt ligands, altering binding of ligands to receptors, inhibiting β-catenin translocation, or by regulating extra-follicular dermal Wnt and Wnt inhibitors.
How to tune Dendritic Spine Morphology
We have already encounter Brain-Derived Neurotropic Factor (BDNF) in an earlier post. You could think of BDNF as brain fertilizer.
“Older people and anyone with Retts Syndrome are likely to benefit from more NGF (Nerve Growth Factor). In autism it appears possible that there was too much NGF and BDNF at a very early age, with levels then changing. High levels of NGF and BDNF look a bad idea. A lot more research is needed to understand what determines NGF and BDNF levels. It appears that BDNF may stay high in autism, but NGF levels.”
It has been shown that BDNF and Wnt signaling together regulate dendritic spine formation.
So, since in autism we have excess BDNF as the brain is developing, this might explain there are too many dendritic spines in autistic brains. Too many spines and the wrong morphology (shape) would explain very many issues that have gone “wrong” in autistic brains.
Here, we show that Wnt signaling inhibition in cultured cortical neurons disrupts dendritic spine development, reduces dendritic arbor size and complexity, and blocks BDNF-induced dendritic spine formation and maturation. Additionally, we show that BDNF regulates expression of Wnt2, and that Wnt2 is sufficient to promote cortical dendrite growth and dendritic spine formation. Together, these data suggest that BDNF and Wnt signaling cooperatively regulate dendritic spine formation.
BDNF overexpression rapidly and robustly increases primary dendrite formation in cortical neurons (Horch et al., 1999; McAllister et al., 1997; Wirth et al., 2003). We reproduced this finding, and found that this increase was not blocked by overexpression of the Wnt inhibitors (Fig. S2), indicating that some aspects of BDNF modulation of dendrites remain intact in the presence of Wnt inhibitors. To further assess whether expression of the Wnt inhibitors impaired the signaling ability of BDNF, we analyzed autocrine induction of c-Fos expression by BDNF overexpression. c-Fos is an immediate early gene whose transcription is rapidly upregulated by BDNF (Calella et al., 2007; Gaiddon et al., 1996). We found that BDNF induced c-Fos expression was not reduced in neurons overexpressing any of the four Wnt inhibitors, suggesting that the ability of the inhibitors to interfere with BDNF-induced spine formation and spine head width expansion was not a result of decreased levels of BDNF signaling (Fig. S3).
Wnt2 overexpression is sufficient to increase cortical dendrite length. (A) Representative cortical neurons expressing either EV or Wnt2. Quantification of the total dendrite length per neuron (B) and the number of dendritic endpoints per neuron (C) for ...
Wnt2 overexpression increases dendritic protrusion density and influences spine shape on cortical neurons. (A) Representative dendritic segments of cortical neurons expressing either EV or Wnt2. (B) Quantification of dendritic protrusion density. (C) ...
Wnt inhibition and dendritic spine maturation
We found that a series of different Wnt signaling inhibitors were able to block BDNF-induced increases in dendritic spine density and dendritic spine head width
I think all this existing science really tells us a lot.
Back in the slow lane
In cancer research, decades have already been spent investigating Wnt signaling.
Drugs that Enhance Wnt Signaling
Back in my world, with a little help from Google scholar, I rapidly find that drugs already exist that affect Wnt signaling. Some very familiar names pop up.
SummaryStatins improve recovery from traumatic brain injury and show promise in preventing Alzheimer disease. However, the mechanisms by which statins may be therapeutic for neurological conditions are not fully understood. In this study, we present the initial evidence that oral administration of simvastatin in mice enhances Wnt signaling in vivo. Concomitantly, simvastatin enhances neurogenesis in cultured adult neural progenitor cells as well as in the dentate gyrus of adult mice. Finally, we find that statins enhance Wnt signaling through regulation of isoprenoid synthesis and not through cholesterol. These findings provide direct evidence that Wnt signaling is enhanced in vivo by simvastatin and that this elevation of Wnt signaling is required for the neurogenic effects of simvastatin. Collectively, these data add to the growing body of evidence that statins may have therapeutic value for treating certain neurological disorders.Simvastatin rescues cerebrovascular and memory-related deficits in mouse models of Alzheimer disease (AD) (Li et al., 2006; Tong et al., 2009, 2012), and recent meta-analysis of clinical studies concluded that statins provide a slight benefit in the prevention of AD and all-type dementia (Wong et al., 2013). While these effects have been attributed to reduction of inflammation, reduced oxidative stress, upregulated PI3K/AKT signaling, and enhanced neurogenesis, the mechanisms by which statins are beneficial in neurological disorders are not fully understood.Simva is under investigation for its potential therapeutic effects outside of hyperlipidemia treatment. While statins have been reported to enhance Wnt signaling in vitro, it was heretofore not known whether statins can enhance this pathway in vivo and in the context of neurogenesis. Here we provide evidence that oral simva treatment enhances Wnt signaling in the mammalian adult hippocampus. This is significant in that aside from lithium, no other clinically approved compound has been demonstrated to enhance Wnt signaling in the brain
You will find the element Lithium in your smart phone battery, but it is also a drug.
Lithium is useful in the treatment of bipolar disorder. Lithium salts may also be helpful for related diagnoses, such as schizoaffective disorder and cyclic major depression. The active part of these salts is the lithium ion Li+.
But, not surprisingly, Lithium has other effects, like activating Wnt signaling.
Drugs that inhibit Wnt Signaling
There are drugs with the opposite effect, inhibiting Wnt signaling.
Abstract
In past years, the canonical Wnt/β-catenin signaling pathway has emerged as a critical regulator of cartilage development and homeostasis. FRZB, a soluble antagonist of Wnt signaling, has been studied in osteoarthritis (OA) animal models and OA patients as a modulator of Wnt signaling. We screened for FDA-approved drugs that induce FRZB expression and suppress Wnt/β-catenin signaling. We found that verapamil, a widely prescribed L-type calcium channel blocker, elevated FRZB expression and suppressed Wnt/β-catenin signaling in human OA chondrocytes. Expression and nuclear translocation of β-catenin was attenuated by verapamil in OA chondrocytes. Lack of the verapamil effects in LiCl-treated and FRZB-downregulated OA chondrocytes also suggested that verpamil suppressed Wnt signaling by inducing FRZB. Verapamil enhanced gene expressions of chondrogenic markers of ACAN encoding aggrecan, COL2A1 encoding collagen type II α1, and SOX9, and suppressed Wnt-responsive AXIN2 and MMP3 in human OA chondrocytes. Verapamil ameliorated Wnt3A-induced proteoglycan loss in chondrogenically differentiated ATDC5 cells. Verapamil inhibited hypertrophic differentiation of chondrocytes in the explant culture of mouse tibiae. Intraarticular injection of verapamil inhibited OA progression as well as nuclear localizations of β-catenin in a rat OA model. We propose that verapamil holds promise as a potent therapeutic agent for OA by upregulating FRZB and subsequently downregulating Wnt/β-catenin signaling.
AbstractConstitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed a repositioning screen for WNT-TCF response blockers aiming to recapitulate the genetic blockade afforded by dominant-negative TCF. We report that Ivermectin inhibits the expression of WNT-TCF targets, mimicking dnTCF, and that its low concentration effects are rescued by direct activation by TCFVP16. Ivermectin inhibits the proliferation and increases apoptosis of various human cancer types. It represses the levels of C-terminal β-CATENIN phosphoforms and of CYCLIN D1 in an okadaic acid-sensitive manner, indicating its action involves protein phosphatases. In vivo, Ivermectin selectively inhibits TCF-dependent, but not TCF-independent, xenograft growth without obvious side effects. Analysis of single semi-synthetic derivatives highlights Selamectin, urging its clinical testing and the exploration of the macrocyclic lactone chemical space. Given that Ivermectin is a safe anti-parasitic agent used by > 200 million people against river blindness, our results suggest its additional use as a therapeutic WNT-TCF pathway response blocker to treat WNT-TCF-dependent diseases including multiple cancers.
Previous studies have revealed that its anti-tumor function could be attributed to its ability to suppress the abnormal Wnt/β-catenin signaling pathway
What about hair loss/gain?
To quote from the previous study on hair loss gain:-
“Using this new knowledge, we now know that Wnt activity can be modulated by adjusting the secretion of Wnt ligands, altering binding of ligands to receptors, inhibiting β-catenin translocation, or by regulating extra-follicular dermal Wnt and Wnt inhibitors.”
We have now learnt that the drug Verapamil is thought to be a Wnt inhibitor. So it would be fair to assume that hair loss would be reported as a side effect of using Verapamil. Indeed it is.
Dermatologic side effects have included rash (up to 1.4%). Diaphoresis has been reported with intravenous verapamil. Arthralgia and rash, exanthema, hair loss, hyperkeratosis, macules, sweating, urticaria, Stevens-Johnson syndrome, and erythema multiforme have been reported during open trials/postmarketing experience.
What about Statins and hair?
So many millions of people take statins, of course somebody would claim it causes hair loss (alopecia). I think it should cause hair gain. As with Verapamil the effect on the hair growth would be much greater if it was applied to the skin and not taken orally. Maybe older people would not go to the doctor to complain about hair gain?
Summary
· As hair loss is a generally accepted male characteristic, drug-induced alopecia may be mistaken as part of a natural process and therefore under reported.
· There have been reports of alopecia associated with the use of all UK licensed statins but there is insufficient data to confidently attribute hair loss to statin use.
· Case studies suggest an association but as yet there is insufficient information to suggest a mechanism, make comparisons of the individual incidence of alopecia between the various statins or propose a class effect.
· The greatest number of reports of alopecia is for simvastatin but this may be related to a greater market share or length of time on market.
It would seem that enough people lose hair from Verapamil for it to be a published side effect. The same is not true for statins and I think hair loss may be coincidental.
But, maybe too much and too little Wnt signaling cause hair loss ?
Recall earlier in this post that Hans Otto Kalkman suggested that both too much and too little Wnt might cause similar behavioral and cognitive symptoms. Perhaps the same is true with hair growth.
The canonical Wnt pathway plays a role in dendrite growth and suboptimal activity negatively affects the dendritic arbor. In principle, this provides a logical explanation as to why both hypo- and hyperactivity may generate a similar set of behavioral and cognitive symptoms.
For optimal hair growth perhaps there is an optimal amount of Wnt signaling?
That might explain why a small number of people find Wnt inhibitors (Verapamil) and drugs that enhance Wnt (statins) cause hair loss.
That might mean that people with very full hair have optimal Wnt signaling?
So advise Homer Simpson to find out whether his Wnt signaling is hyper or hypo. Then he might find either simvastatin or verapamil brings back his full head of hair.
Wnt signaling and Diabetes
Yet again we find another connection between Diabetes and autism.
In the pancreas β-cells produce insulin. In diabetics these β-cells get destroyed. It appears that Wnt signaling is involved in controlling these β-cells. It has been proposed that they could be protected via this pathway.
Role of Wnt signaling in the development of type 2 diabetes.
Abstract
Here, we review emerging new evidence that Wnt signaling influences endocrine pancreas development and modulates mature β-cell functions including insulin secretion, survival and proliferation. Alterations in Wnt signaling might also impact other metabolic tissues involved in the pathogenesis of diabetes, with TCF7L2 proposed to modulate adipogenesis and regulate GLP-1 production. Together, these studies point towards a role for Wnt signaling in the pathogenesis of type 2 diabetes, highlighting the importance of further investigation of this pathway to develop new therapies for this disease.
As with autism and cancer, the people with diabetes are also perhaps not benefiting from the latest science.
Oral verapamil administration prevents β-cell apoptosis and STZ-induced diabetes.
The End.
